News | December 30, 2014

Mechanical Engineer Invents Heart Valve Replacement Procedure that Does Not Disturb the Heart

Procedure places one-way valve in a vein or artery near the heart to restore healthy pumping efficiency

December 30, 2014 — After watching his father die from heart valve disease, a mechanical engineer used his expertise in fluid dynamics to develop a first-of-its-kind procedure to replace leaking or regurgitating heart valves without touching the heart.

"The human body is merely a glorified mechanical device," said Bret Park, inventor of the One-Way Heart Assist Valve. "My background in turbomachinery and the study of fluid movement gave me a unique perspective into the workings of the cardiovascular system."

The One-Way Heart Assist Valve technology involves installing a new valve without cutting or tampering with the heart itself. This is accomplished by placing the one-way valve in a vein or artery upstream or downstream from the heart.

"This procedure allows the native heart to regain healthy pumping efficiency," Park said. "Although my invention came too late for my dad, I believe it will save millions of others from suffering the same fate."

Approximately 23 million people worldwide are afflicted with congestive heart failure (CHF) and over 5.8 million in the United States, according to American Heart Association and National Center for Biotechnology Information. CHF is the chronic inability of the heart to pump blood efficiently and is often caused by heart valve disease (HVD).

Existing medical solutions for CHF and HVD usually involve major surgery, which cuts into the heart itself, or a heart transplant. The surgeries have serious side effects and are considered too risky for a high percentage of patients. Furthermore, only 1 percent of those in need of a new heart actually receive a transplant.

Park's company, Savant Holdings, LLC, estimates that the One-Way Heart Assist Valve technology could help approximately 70 percent of CHF and HVD patients. The invention may be an option in the following situations:


  • Patients who are too weak for heart valve surgery
  • Patients who need a new heart
  • Patients who need but do not qualify for a heart transplant or die waiting
  • Patients who desire a better option than the standard valve replacement
  • Patients that have a less-than-severe condition and would otherwise postpone a valve replacement 


Savant Holdings has shown that this technology works mechanically and is now trying to raise sufficient funds through the crowdfunding website Indiegogo so that animal testing can begin. The availability of funds will determine how soon this technology is approved by the U.S. Food and Drug Administration (FDA) and available for medical use.

For more information:

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Overlay Init